Anna C. Renner

Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms

ACS Medicinal Chemistry Letters July 10, 2026 Anna C. Renner, Robert B. Kargbo

High Resolution Image Download MS PowerPoint Slide The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds,...

DOI: 10.1021/acsmedchemlett.6c00364 (opens in new tab) Aerosol Precision medicine Nanotechnology

Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine–DMT Formulations

ACS Medicinal Chemistry Letters December 16, 2025 Anna C. Renner, Robert B. Kargbo

Emerging psychedelic therapeutics increasingly rely on mechanistic precision, receptor selectivity, and pharmacokinetic control. Recent inventions introduce simplified iboga analogs with tunable polypharmacology, real-time EEG biomarkers that individualize psilocybin dosing, and standardized harmine-DMT ratios with high bioavailability. Together, these innovations form a coherent framework for...

DOI: 10.1021/acsmedchemlett.5c00714 (opens in new tab) Full text (opens in new tab) Psilocybin Electroencephalography Hallucinogen Investigational drugs +1

Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric Therapeutics

ACS Medicinal Chemistry Letters December 16, 2025 Anna C. Renner, Robert B. Kargbo

New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 for objective PTSD detection; benzocyclobutenyl-methylamine modulators that normalize neuronal hyperexcitability; and templated-carrier sublingual 5-MeO-DMT formulations enabling controlled, nonhallucinogenic neuroplasticity. Together, these approaches...

DOI: 10.1021/acsmedchemlett.5c00716 (opens in new tab) Full text (opens in new tab) Scalability Computational biology Precision medicine Bioinformatics

Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy

ACS Medicinal Chemistry Letters October 10, 2025 Anna C. Renner, Robert B. Kargbo

A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns. Together, these inventions advance formulation, mechanistic selectivity, and translational biomarkersoffering a chemistry-enabled path to scalable...

DOI: 10.1021/acsmedchemlett.5c00595 (opens in new tab)